Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progesterone for breast development in trans women
NL-OMON49293Phase 2Completed
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of progesterone and estradiol in Hypogonadism and Gender incongruence (GI) (6 arms), sponsored by Vrije University Medical Center. Primary endpoints: Change in breast volume and Bra cup size. Started Mar 2021; status: completed.
02
Drugs
progesteroneestradiol
03
Conditions
HypogonadismGender incongruence (GI)
Beyond the preview
Go deeper on NL-OMON49293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49293.